KemPharm Logo
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
February 23, 2022 07:30 ET | KemPharm
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty...
KemPharm Logo
KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
January 19, 2022 16:21 ET | KemPharm
KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021; Available Cash and...
KemPharm Logo
KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
January 12, 2022 07:30 ET | KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla., Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm,...
KemPharm Logo
KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
January 11, 2022 07:30 ET | KemPharm
Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) --...
KemPharm Logo
KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
January 06, 2022 07:30 ET | KemPharm
CELEBRATION, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced...
KemPharm Logo
KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
December 20, 2021 07:30 ET | KemPharm
CELEBRATION, Fla., Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced...
KemPharm Logo
KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
December 14, 2021 07:30 ET | KemPharm
Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects...
KemPharm Logo
KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021
December 13, 2021 16:05 ET | KemPharm
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Logo
KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
December 13, 2021 07:30 ET | KemPharm
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
KemPharm Logo
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
November 10, 2021 16:05 ET | KemPharm
Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET ...